MENU

Here’s why all insane valuations will eventually become sane one way or another

The share market, and most other asset classes, have reached continuous highs over the last couple of years.

We’ve seen other types of valuations used, like a multiple of sales, to justify a high valuation.

Anyone paying for a businesses valued at over 100x the last year’s earnings, or even next year’s earnings, are pricing in some big expectations.

Some of the shares to trade with those huge triple digit valuations in recent history include Kogan.Com Ltd (ASX: KGN), Medical Developments International Ltd (ASX: MVP) and Afterpay Touch Group Ltd (ASX: APT).

I may have cherry picked those examples, but they have all fallen significantly since their all-time highs. If you buy at an extremely high valuation the growth expectations are priced in for years.

That means there’s a period of several financial years where the market may decide your hotshot stock isn’t worth as much as you think.

Rising interest rates mean that only the worthiest of fast-growing businesses can command such a multiple. WiseTech Global Ltd (ASX: WTC) has fallen more than 25% since September yet it still trades at 81x FY19’s estimated earnings. It’s trading at 39x FY21’s earnings, which is still a hefty price.

Electronic PCB software market darling Altium Limited (ASX: ALU) is ‘only’ trading at 40x FY19’s earnings – it seems like a bargain compared to WiseTech!

Of course, the same can be said in reverse. A business that is trading with a very low valuation and achieves profit growth will eventually be too cheap for the market to ignore. I thought Zenitas Healthcare Limited (ASX: ZNT) was too cheap to ignore for a business growing nicely organically.

Foolish takeaway

Two shares that seem to be trading very cheaply to me are Paragon Care Ltd (ASX: PGC) and Apiam Animal Health Ltd (ASX: AHX). They are both achieving decent organic growth and are trading at around 10x FY19’s estimated earnings.

Another share that looks good value to me is this top growth stock which grew profit by 30% in FY18 alone.

Is this the best dividend stock with plenty of growth too?

You might not know this market leader's name, but it's rapidly expanding into a highly profitable niche market here in Australia. Even better, the shares boast a strong, fully franked dividend that should balloon in the years to come. In other words, we're looking at the holy grail of incredible long-term growth potential AND income you can watch accruing in your account in real time!

Simply click here to grab your FREE copy of this up-to-the-minute research report on our #1 dividend share recommendation now.

Motley Fool contributor Tristan Harrison owns shares of Altium, Apiam Animal Health Ltd, and Paragon Care Limited. The Motley Fool Australia owns shares of AFTERPAY T FPO, Altium, and WiseTech Global. The Motley Fool Australia has recommended Kogan.com ltd, Paragon Care Limited, and Zenitas Healthcare Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…

Including:

The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!